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Optimal HIV-1 infectivity requires the presence of both the viral factor Nef and the cellular protein cyclophilin A (CyPA)
during virion assembly. These two proteins are integral components of HIV-1 particles. Both CyPA and Nef facilitate a step
in the viral life cycle occurring between penetration and reverse transcription, suggesting a common mechanism of action.
Experiments were performed to test the potential interplay of Nef- and CyPA-mediated enhancement of HIV-1 infectivity. In
single-cycle infection assays, nef-defective virions were partially resistant to cyclosporin A (CsA), a drug that inhibits the
binding of CyPA to the HIV-1 Gag precursor and CyPA incorporation into virions. Genetic dissection of the relative
contributions of Nef and the cyclophilin A-Gag interaction to HIV-1 infectivity demonstrated the independence of these two
effects. Nef was not required for incorporation of CyPA into HIV-1 virions and vice-versa. Surprisingly, CyPA-deficient virions
remained sensitive to inhibition by CsA, in a manner that depended strongly on the presence of a functional nef gene. These
results demonstrate that Nef and CyPA act independently to render HIV-1 particles fully infectious. They further suggest that
in addition to blocking the CyPA-Gag interaction, CsA can also inhibit HIV-1 replication through a novel mechanism involving
suppression of Nef-directed enhancement of virus infectivity. © 1998 Academic Press
INTRODUCTION
HIV-1 Nef is required for efficient viral replication in
primary CD41 T cells and macrophages, as well as in
many T cell lines (de Ronde et al., 1992; Zazopoulos and
Haseltine, 1993; Miller et al., 1994; Spina et al., 1994).
Several groups have previously shown that nef-defective
virions are approximately five- to 10-fold less infectious
than wild-type HIV-1 when tested in single-cycle infection
assays using CD4-expressing HeLa cells or the CEM
human T cell line as targets (Aiken and Trono, 1995;
Chowers et al., 1994; Miller et al., 1994; Schwartz et al.,
1995). Although it is unclear what precise step in the
HIV-1 life cycle Nef facilitates, two lines of evidence
implicate an early postentry event. First, measurements
of virus internalization by cells reveal no differences
between wild-type and nef-defective HIV-1. Second,
pseudotyping by the envelope glycoproteins of the am-
photropic murine leukemia virus (MuLV) fails to comple-
ment the Nef defect, suggesting that Nef does not facil-
itate CD4-dependent entry (Aiken and Trono, 1995; Miller
et al., 1995). This conclusion is further supported by the
observation that Nef enhances the infectivity of HIV-
1(MuLV) pseudotypes irrespective of the presence or
absence of CD4 on the target cells (Aiken and Trono,
1995). Although Nef does not appear to enhance HIV-1
entry, nef-defective HIV-1 undergoes inefficient reverse
transcription in target cells, even though the virions
themselves exhibit normal levels of reverse transcriptase
activity (Aiken and Trono, 1995; Chowers et al., 1995;
Schwartz et al., 1995). Nef-defective virions are impaired
for synthesis of even the earliest products of reverse
transcription in target cells (Aiken and Trono, 1995). It is
therefore plausible that Nef facilitates a step of the HIV-1
life cycle between entry and initiation of reverse tran-
scription—namely, virus uncoating. However, little is
known regarding the molecular events associated with
retroviral uncoating. The observation that Nef is incorpo-
rated into HIV-1 particles and is specifically cleaved by
the viral protease (Pandori et al., 1996; Welker et al.,
1996) suggests that Nef may enhance HIV-1 infection by
acting directly in virions.
In addition to Nef, much attention has been focused on
a human cellular protein that is also required for efficient
HIV-1 infection. Cyclophilin A (CyPA), a peptidyl proline
isomerase, is the target of the immunosuppressive drug
cyclosporin A (CsA). CsA inhibits HIV-1 replication in
primary T cells and established T cell lines (Karpas et al.,
1992; Franke et al., 1994; Rosenwirth et al., 1994; Thali et
al., 1994). This activity is independent of the inhibitory
effects of CsA on T cell activation, however, because
nonimmunosuppressive analogs of CsA also block HIV-1
replication (Rosenwirth et al., 1994; Billich et al., 1995).
CyPA binds to the capsid region of the HIV-1 Gag pre-
cursor (Luban et al., 1993) and is incorporated into HIV-1
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particles through an interaction with a proline-rich region
of capsid (Franke et al., 1994; Thali et al., 1994). Muta-
tions in this region that block CyPA binding render HIV-1
particles poorly infectious. Importantly, the mechanisms
by which Nef and CyPA enhance HIV-1 infectivity appear
intriguingly similar. Both Nef and CyPA are required at
the time of HIV-1 particle formation to render HIV-1 viri-
ons fully infectious, and both proteins are components of
HIV-1 particles. The requirement for CyPA, like Nef, is not
relieved by pseudotyping with the amphotropic MuLV
envelope glycoprotein, indicating that the requirement
for Gag-CyPA binding is independent of CD4-mediated
HIV-1 entry. Furthermore, both CyPA-deficient and nef-
defective HIV-1 particles contain wild-type levels of en-
dogenous reverse transcriptase activity but undergo in-
efficient reverse transcription in target cells. Recent ob-
servations from this laboratory have also demonstrated
that pseudotyping HIV-1 particles by the envelope glyco-
protein of vesicular stomatitis virus (VSV-G) suppressed
the requirement for Nef (Aiken, 1997). Infection by HIV-
1(VSV) pseudotypes was blocked by preventing endoso-
mal acidification, indicating an endocytic route of entry.
Inhibition of HIV-1 infectivity by CsA was also relieved in
these pseudotypes; however, pseudotyping by VSV-G
had no effect on the phenotype of HIV-1 gag mutants
defective for CyPA binding. These results suggested a
possible mechanistic overlap between Nef-mediated
HIV-1 infectivity enhancement and inhibition of HIV-1
infectivity by CsA.
Due to the similarities between Nef- and CyPA-medi-
ated HIV-1 infectivity enhancement, experiments were
designed to test whether Nef and CyPA employ a com-
mon mechanism to enhance HIV-1 infectivity. Viruses
containing mutations in gag inhibiting binding of CyPA, in
nef, or in both genes were produced by transfection of
293T cells to circumvent problems associated with pro-
duction of replication-defective virions. Quantitative sin-
gle-cycle infection assays were performed to determine
the relative infectivity of mutant virions. Using this assay,
the inhibitory effects of CsA on the infectivity of the
mutants were also quantified. The results demonstrate
that Nef and the CyPA-Gag interaction are independently
required to enhance HIV-1 infectivity and suggest that
Nef-directed HIV-1 infectivity enhancement represents
an additional viral function that is inhibited by CsA.
RESULTS
Nef-defective HIV-1 is partially resistant to
cyclosporin A
Treatment of cells producing HIV-1 with CsA blocks
incorporation of CyPA into progeny virions and reduces
viral infectivity (Franke et al., 1994; Thali et al., 1994). To
dissect the effects of Nef and CyPA on HIV-1 infectivity,
CsA was used to generate CyPA-deficient viruses. Wild-
type and nef-defective HIV-1 stocks were produced by
transfecting 293T cells with HIV-1 molecular clones and
culturing in the presence of various concentrations of
CsA. The resulting HIV-1-containing supernatants were
assayed for reverse transcriptase activity and titrated by
infecting the P4 indicator cell line. P4 cells express CD4,
which renders them susceptible to HIV-1 infection, and
contain an integrated Escherichia coli lacZ gene driven
by the HIV-1 LTR. Upon infection with HIV-1, Tat produc-
tion from the integrated provirus leads to activation of the
lacZ reporter, resulting in synthesis of b-galactosidase in
these cells. Infected cells are identified by staining with
X-gal 48 h postinoculation, allowing quantitation after a
single round of HIV-1 infection. Using this single-cycle
infection assay, the relative infectivity of a virus stock
was calculated as the number of infected cells per unit of
reverse transcriptase activity.
CsA caused a dose-dependent inhibition of wild-type
HIV-1 infectivity reaching a level of 75% at 10 mM drug
(Fig. 1B). Virions produced in this concentration of CsA
contained undetectable levels of CyPA (Fig. 2). Higher
FIG. 1. Effects of cyclosporin A on wild-type and nef-defective
HIV-1 infectivity. Viruses were produced by culturing transfected
293T cells in the presence of the indicated concentrations of cyclo-
sporin A. Culture supernatants were assayed for reverse transcrip-
tase activity and their titers determined by infecting P4 indicator
cells. (A) The ordinate values represent the number of infectious
units per unit reverse transcriptase activity. R9: wild-type HIV-1;
R9DN: nef-defective HIV-1. Shown are the mean values of triplicate
infections, with error bars representing 1 SD from the mean. The
data are representative of two independent experiments. (B) The
data shown in (A) are represented as the percentage by which viral
infectivity is reduced by the indicated concentrations of CsA.
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levels of CsA (20 mM) were toxic to 293T cells and
decreased virus production without further inhibiting viral
infectivity. Nef-defective virions were less infectious than
wild-type HIV-1 at all concentrations of CsA tested (Fig.
1A). However, HIV-1Dnef was partially resistant to CsA,
which caused 40% inhibition at 10 mM (Fig. 1B).
Nef and CyPA are independently incorporated
into HIV-1 particles
The decreased sensitivity of nef-defective HIV-1 to inhi-
bition by CsA suggested that Nef and CyPA may act
through a common pathway to enhance HIV-1 infectivity.
To determine whether Nef influences virion incorporation
of CyPA, purified wild-type and nef-defective HIV-1 particles
were analyzed for their CyPA content by immunoblotting.
Samples of viral lysates containing 100 ng of p24, as de-
termined by ELISA, were subjected to electrophoresis on
polyacrylamide gels containing SDS. After transfer of pro-
teins to nitrocellulose, the relative levels of CyPA present
in the particles were assessed by probing the blot with
rabbit antiserum specific for human CyPA. No significant
differences in CyPA content were observed between wild-
type and nef-defective virions (Fig. 2A, lanes 1 and 3) or in
their corresponding envelope-defective variants (lanes 4
and 5). As previously reported (Franke et al., 1994; Thali
et al., 1994), wild-type HIV-1 virions produced in the pres-
ence of 10 mM CsA contained undetectable levels of CyPA
(lane 2). To assess whether equal quantities of viral lysates
were loaded, the blot was reprobed with a CA-specific
monoclonal antibody (Fig. 2B). As expected, the results
confirmed that similar amounts of capsid protein were
present in each lane.
In addition to CyPA, Nef is also a component of HIV-1
virions and is cleaved in virions by the HIV-1 protease
(Pandori et al., 1996; Welker et al., 1996). To ask whether
CsA influences virion incorporation of Nef, the blot shown in
Fig. 2 was reprobed with a rabbit antiserum specific for
HIV-1 Nef. No significant reduction of proteolytically pro-
cessed Nef was observed in virions produced in the pres-
ence of CsA (Fig. 2C, lanes 1 and 2). This result indicates
that CsA does not modulate Nef function by influencing
incorporation of Nef into HIV-1 particles or its subsequent
cleavage by the viral protease.
Nef and the cyclophilin A-Gag interaction
independently enhance HIV-1 infectivity
Previous reports have demonstrated that mutations of
capsid residues glycine 221 or proline 222 to alanine
inhibit CyPA incorporation into HIV-1 virions and reduce
HIV-1 infectivity (Franke et al., 1994; Braaten et al., 1996b).
To genetically dissect the relative contributions of Nef
and CyPA to HIV-1 infectivity, the G221A and P222A
mutations were introduced into HIV-1 proviral DNA con-
structs carrying intact and disrupted nef genes. Viruses
containing the G221A or P222A mutations were pro-
duced in parallel with wild-type and HIV-1Dnef by trans-
fection of 293T cells, and the resulting virus supernatants
assayed for reverse transcriptase activity and titers de-
termined by infecting P4 cells. The infectivities of the
FIG. 3. Nef and the CyPA-Gag interaction independently enhance
HIV-1 infectivity. Viruses were produced by transfection of 293T cells
and were assayed for infectivity using P4 cells as targets. Shown are
the mean values of triplicate infections, with error bars representing 1
SD. The paired solid and open bars are the results of independent virus
stocks. R7:wild-type HIV-1; R7DN:nef-defective HIV-1. R7.221 and
DN.221 contain a mutation of Gly221 of capsid to Ala; R7.222 and
DN.222 contain a mutation of Pro222 to Ala.
FIG. 2. Levels of CyPA in wild-type and nef-defective HIV-1 particles.
Virions produced by transfection of 293T cells were purified by centrif-
ugation through 20% sucrose. The pellets were lysed and subjected to
Western blot analysis using aliquots normalized for p24 content by
ELISA. Proteins were detected with rabbit anti-cyclophilin A (A), mouse
anti-HIV-1 CA (B), and rabbit anti-Nef (C); blots were developed using
chemiluminescent detection. Lane 1: wild-type HIV-1, lane 2: wild-type
HIV-1 produced in the presence of 10 mM cyclosporin A; lane 3:
nef-defective HIV-1, lane 4: env-defective HIV-1; lane 5: env-defective,
nef-defective HIV-1.
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G221A or P222A viruses were reduced to 18 and 33% of
that of wild-type HIV-1 (Fig. 3). These values correlated
well with the relative levels of CyPA present in the viri-
ons, as shown by immunoblot analysis of detergent ly-
sates of purified virions (Fig. 4). Furthermore, the effects
of gag mutations on HIV-1 infectivity were strictly inde-
pendent of the presence of a functional nef gene. For
example, the GagP222A mutation decreased HIV-1 infec-
tivity by threefold regardless of the nef genotype, and Nef
enhanced HIV-1 infectivity by approximately ninefold re-
gardless of the presence of either gag mutation (Fig. 3).
Thus, the effects of the Gag-CyPA interaction and Nef on
HIV-1 infectivity are functionally distinct. This result con-
trasts with the results of previous experiments in which
HIV-1Dnef exhibited a decreased sensitivity to CsA (Fig.
1). This apparent contradiction suggests that inhibition of
HIV-1 infectivity by CsA may be pleiotropic, perhaps
involving a Nef-dependent component.
Cyclosporin A sensitivity correlates
with nef expression
To distinguish the effects of CsA on the Gag-CyPA
interaction from possible inhibition of Nef-enhanced
HIV-1 infectivity, wild-type and nef-defective HIV-1 parti-
cles containing mutations in gag were produced in the
presence and absence of CsA and assayed for infectivity
using P4 cells. Interestingly, mutant virions containing
decreased CyPA levels were significantly inhibited by
CsA (Fig. 5A). Furthermore, CyPA-deficient HIV-1 parti-
cles containing a functional nef gene were inhibited by
CsA to a degree similar to that of wild-type HIV-1. In
contrast, nef-defective viruses were relatively resistant to
the inhibitory effects of CsA irrespective of the ability of
Gag to bind CyPA (Fig. 5B). This result suggested that a
significant component of the inhibitory effect of CsA on
HIV-1 replication is due to inhibition of Nef-mediated
infectivity enhancement.
To determine whether these effects extended to HIV-1
replication, the growth kinetics of wild-type and nef-
defective viruses containing the G221A and P222A mu-
tations were monitored in CEM cells cultured in the
presence and absence of CsA (Fig. 6). The growth of
both gag mutant viruses was delayed relative to wild-
type HIV-1 (Figs. 6C and 6E), to an extent that correlated
with the CyPA levels in the virions (Fig. 4). Similar effects
of CsA were also observed for the nef-defective variants
(Figs. 6B, 6D, and 6E). In most of the CsA-containing
cultures, positive reverse transcriptase activity was de-
tected by 40 days, possibly due to the acquisition of
drug-resistant mutations, as previously described (Aber-
ham et al., 1996). Exceptions include the poorly-replicat-
ing viruses DN.222, R7.221, and DN.221. The replication
kinetics of nef-defective viruses were delayed relative to
their nef1 counterparts (Figs. 6D and 6F), consistent with
the results from single-cycle assays that the effects of
Nef and CyPA on HIV-1 infectivity are independent (Fig.
FIG. 5. Inhibition of HIV-1 infectivity by CsA correlates with the
expression of Nef. Viruses were produced by culturing transfected
293T cells for 2 days in the presence or absence of 10 mM CsA. Virus
stocks were assayed for reverse transcriptase activity and their titers
determined by infecting P4 cells. (A) Shown are the mean values of
triplicate infections, with error bars representing 1 SD. The results are
representative of two experiments. (B) The ratios of the infectivity
values obtained for viruses produced in the absence of CsA to those of
viruses produced in the presence of CsA are shown.
FIG. 4. Effects of gag mutations of HIV-1 packaging of CyPA. Virions
produced by transfection of 293T cells with proviral DNA constructs
were purified by ultracentrifugation through 20% sucrose. Viral pellets
were dissolved in lysis buffer, assayed for p24 content by ELISA, and
subjected to immunoblot analyses. The blots were probed sequentially
with rabbit anti-CyPA (A) and mouse anti-CA (B), and protein bands
were visualized using chemiluminescent detection.
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5). However, in contrast to the previous result that nef-
defective viruses are relatively resistant to CsA when
assayed on P4 cells (Fig. 1), the growth of both nef1 and
nef-defective variants of the gag mutants in CEM cells
was markedly inhibited by CsA (Figs. 6C–6F).
DISCUSSION
Results of experiments presented here demonstrate
that Nef enhances HIV-1 infectivity independently of the
CyPA-Gag interaction. The infectivity of HIV-1 virions con-
taining reduced levels of CyPA by virtue of mutations in
capsid was stimulated by Nef to the same degree as
wild-type virus. This was shown by quantitative single-
cycle infection assays using Hela-CD4 cells as targets
and confirmed by measuring viral replication in CEM
human T cells. Nef-defective HIV-1 contained normal
levels of CyPA, and virions produced in the presence of
CsA exhibited normal amounts of proteolytically cleaved
Nef protein. Thus, virion incorporation of CyPA is not
regulated by Nef and vice-versa.
The observation that Nef and the CyPA-Gag interaction
independently enhance HIV-1 infectivity has implications
for the mechanisms by which these two proteins func-
tion. Both Nef and CyPA appear to act at a step of the
FIG. 6. Cyclosporin A inhibits replication of mutant HIV-1 lacking CyPA. CEM cells were inoculated with aliquots of viruses containing 30,000 cpm
reverse transcriptase activity. After overnight culturing, the cells were pelleted to remove input virus, and cultured in 2 ml media in the presence
(dashed lines) and absence (solid lines) of 2.5 mM CsA. Virus production was monitored periodically by assaying for reverse transcriptase activity
in the supernatants. (A) Wild-type HIV-1. (C) HIV-1 containing a mutation of Pro222 to Ala in capsid. (E) HIV-1 containing a mutation of Gly221 to Ala
in capsid. Replication of the nef-defective variants of R7, R7.222, and R7.221 are shown in (B), (D), and (F), respectively.
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virus infection pathway that follows entry into the target
cell but precedes reverse transcription (Aiken and Trono,
1995; Braaten et al., 1996b; Chowers et al., 1995;
Schwartz et al., 1995; Steinkasserer et al., 1995). Genetic
disruption of Nef, or of the CyPA-Gag interaction, results
in the formation of normal amounts of virus particles that
appear normal both structurally and biochemically
(Aiken, unpublished observations; Braaten et al., 1996b;
Miller et al., 1995). Both proteins are significant compo-
nents of virions (Franke et al., 1994; Thali et al., 1994;
Pandori et al., 1996; Welker et al., 1996). Although the
subviral localization of Nef is unknown, CyPA is probably
associated with the viral core through its interaction with
capsid. Thus, it was not difficult to imagine that both Nef
and CyPA might use a common mechanism to facilitate
virus uncoating—a step that follows entry but precedes
reverse transcription. If this were the case, one might
have expected some overlap between the effects of
mutations abolishing nef expression and those prevent-
ing CyPA incorporation. Because the effects were strictly
independent, it is likely that these two proteins enhance
HIV-1 infectivity by separate mechanisms.
In the single-cycle infectious assays used here, a
fourfold reduction of wild-type HIV-1 infectivity was ob-
served when the virus was produced in the presence of
10 mM CsA. This concentration was sufficient to virtually
abolish CyPA incorporation into HIV-1 particles. The fact
that CsA and mutations in gag only partially inhibited
infection in this assay allowed dissection of the relative
contributions of Nef and CyPA to viral infectivity. Nef-
defective virions were relatively resistant to CsA, as their
infectivity was inhibited only twofold by 10 mM CsA.
Other workers reported a 9- to 14-fold reduction of HIV-1
infectivity by CsA using a nef-defective HIV-1 carrying a
chloramphenicol acetyl transferase (CAT) gene (Thali et
al., 1994). Although the cause of the decreased effects of
CsA in the present experiments is not clear, one possi-
bility may be the different assay systems used: the pre-
vious results were obtained using bulk assays of CAT
activity in cell lysates, while the assay used in the
present study involved counting individual infected cells.
In this system, some variation in the intensity of blue
staining of infected cells is always evident, but very dark
and very light stained cells are scored as single infec-
tious units. If CsA-treatment results in a shift in the
relative proportion in the number of light or dark blue
cells, a greater or lesser effect would be observed by
assaying enzyme activity in cell lysates. The signal from
bulk assays of reporter activity may thus be amplified by
differences in reporter expression arising from delays in
the time of integration, as well as effects on postintegra-
tional processes such as transcriptional activation or
virus-induced cytotoxicity. In support of this, preliminary
results from this laboratory suggest that the apparent
effects of CsA are markedly enhanced by assaying bulk
lysates of infected cells for soluble b-galactosidase ac-
tivity (C. Aiken, unpublished observations). Another pos-
sible explanation is that the cell lines used to produce
the viruses may differ in CyPA concentrations, resulting
in modulation of the phenotype of viruses produced in
the presence of CsA. Cell-specific effects related to in-
tracellular CyPA concentrations have recently been re-
ported for the replication of the HIV-1 GagP222A mutant
(Ackerson et al., 1998).
HIV-1 particles produced in the presence of 10 mM
CsA are devoid of CyPA, and it has generally been
concluded that disruption of the CyPA-Gag interaction is
the mechanism through which CsA suppresses HIV-1
replication. Evidence for this comes from the fact that
mutations conferring resistance to cyclosporins map to
the capsid region of Gag (Aberham et al., 1996; Braaten
et al., 1996a). In addition, replacement of the CA-p2
region of the simian immunodeficiency virus (SIV), a virus
that is resistant to CsA, by the corresponding region from
HIV-1 renders SIV sensitive to the drug (Dorfman and
Gottlinger, 1996). These findings argue strongly for the
CyPA-Gag interaction as the principal target for CsA
inhibition of HIV-1 replication.
Evidence presented here suggests that in addition to
preventing virion incorporation of CyPA, CsA may block
HIV-1 replication by inhibiting an additional viral function.
First, single-cycle infection assays revealed that nef-
defective virions exhibited a two- to threefold reduced
sensitivity to CsA relative to wild-type HIV-1. Second, CsA
also reduced the infectivity of HIV-1 mutants deficient in
CyPA by a similar degree as that of the wild-type virus
and delayed the replication of these mutant viruses in a
human T cell line. Together, these results suggest that
CsA may target another viral function besides the CyPA-
Gag interaction. The observation that CsA sensitivity
correlates with the presence of a functional nef gene
strongly suggests that CsA can inhibit the ability of Nef to
enhance HIV-1 infectivity. In support of this interpretation,
recent results from this laboratory have demonstrated
that pseudotyping HIV-1 by the glycoprotein of vesicular
stomatitis virus suppresses both the requirement for Nef
and the sensitivity to CsA but does not relieve the infec-
tivity impairment resulting from a gag mutation that in-
hibits CyPA binding (Aiken, 1997). This finding further
demonstrates a functional distinction between CyPA-Gag
binding and inhibition of HIV-1 infectivity by CsA. Never-
theless, CsA effectively inhibited the growth of both wild-
type and nef-defective HIV-1 in CEM cells. This apparent
discrepancy may be due to the differing dynamics of
virus replication in continuous culture vs those in single-
cycle infection assays. The two- to threefold higher sen-
sitivity of nef1 HIV-1 to CsA may not be apparent in viral
growth curves where the mode of transmission can
switch from cell-free infection to a cell-to-cell mode after
the first round. Thus, it is probable that the CyPA-Gag
interaction is the major target for CsA inhibition of HIV-1
replication in T cells. Nevertheless, CsA inhibition of
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Nef-dependent HIV-1 infectivity enhancement represents
an effect of the drug that may be relevant in some
experimental systems, including those measuring virus
infection during a single round.
How might CsA inhibit Nef function? CsA binds to
CyPA, promoting the formation of a ternary complex with
calcineurin (CN) and blocking the activity of this protein
phosphatase essential for efficient T-cell activation.
However, nef-defective HIV-1 was also resistant to ana-
logs of CsA that are incapable of mediating complex
formation with CN (C. Aiken, unpublished observations).
This activity of CsA is therefore unlikely to mediate the
apparent inhibition of Nef. Nef contains a highly con-
served PGPG sequence element that forms part of a turn
on the protein surface (Shugars et al., 1993; Lee et al.,
1996) that is reminiscent of the CyPA-binding domain of
capsid (Gamble et al., 1996). Binding of CyPA to Nef has
been observed in vitro (Billich et al., 1995), and CyPA
peptidylprolyl isomerase activity may be required for the
proper folding or intracellular transport of Nef. CsA does
not appear to affect Nef synthesis or stability because
the levels of Nef protein in transfected cells are not
reduced by CsA (C. Aiken, unpublished observations).
Furthermore, preliminary results indicate that CsA treat-
ment of nef-expressing T cells does not significantly
inhibit another activity of Nef, CD4 downregulation. CD4
downregulation and HIV-1 infectivity enhancement are
genetically distinct activities of the viral protein (Gold-
smith et al., 1995; Saksela et al., 1995), and CyPA binding
to Nef may be required for one activity and not the other.
Alternatively, CsA treatment of cells could interfere with a
downstream effector molecule, such as a Nef-associated
protein kinase, through which Nef may mediate HIV-1
infectivity enhancement (Sawai et al., 1994; Saksela et
al., 1995). Resolution of these issues will require a more
detailed understanding of the biochemical mechanism
by which Nef enhances HIV-1 infectivity.
MATERIALS AND METHODS
Cells and viruses
293T cells and the Hela-CD4/LTR-lacZ indicator cell
line P4 (Charneau et al., 1992) were cultured in Dul-
becco’s modified Eagle’s medium (DMEM, Cellgro)
supplemented with 10% fetal bovine serum (FBS, At-
lanta Biologicals) and penicillin plus streptomycin
(Cellgro). The human T cell lines CEM, SupT1, and
Jurkat were cultured in RPMI 1640 containing 10% FBS
and penicillin plus streptomycin. The viruses used in
this study were derived from R7, a full-length clone of
HIV-1 HXB2 containing a complete nef open-reading
frame (Kim et al., 1989). R7DN contains a frameshift
mutation at the XhoI site in nef and has been charac-
terized previously (Aiken et al., 1994). Capsid muta-
tions were created by oligonucleotide-directed mu-
tagenesis using the polymerase chain reaction to am-
plify a BssHII-to-SpeI fragment. PCR-amplified regions
were subjected to DNA sequencing using Sequenase
(Amersham) and cloned into R7. R9 and R9DN are
full-length plasmid clones of HIV-1 that were created
by replacing BssHII-to-BamHI fragments of R7 or
R7DN, respectively, with the corresponding fragment
from pNL4–3 (Adachi et al., 1986), as previously de-
scribed (Gallay et al., 1995). In these viruses, the gag,
pol, and gp120 region of env are derived from NL4– 3,
while the LTRs and nef are from HXB2. These
viruses therefore encode functional vpu and vpr
genes. HIV-1 stocks were produced by transfection of
293T cells using the calcium phosphate-BBS method
(Chen and Okayama, 1987). After overnight incubation
with the precipitates in an incubator set at 35°C and
3% CO2, the cells were washed once with phosphate
buffered saline (PBS) and the medium replaced. In
experiments involving cyclosporin A (Sigma) the drug
was added as a 1 mM stock solution in absolute
ethanol to achieve the desired final concentrations in
culture media (1 to 20 mM). Control viruses were
produced in the presence of equivalent concentrations
of ethanol. Two days after transfection, virus-contain-
ing supernatants were harvested, passed through 0.45
mm cellulose acetate syringe filters, and assayed for
reverse transcriptase activity and virus infectivity prior
to storage at 275°C.
Infections
For single-cycle assays of HIV-1 infectivity, P4 cells
(4 3 104) were plated in 12-mm wells and infected in
triplicate 1 day later with 0.25 ml of virus dilutions con-
taining DEAE-dextran (20 mg/ml). Two hours later, com-
plete medium (2 ml) was added. Cells were subse-
quently cultured for 2 days and were fixed and stained
with 5-bromo-4-chloro-3-indolyl-galactopyranoside (X-
gal) as described (Kimpton and Emerman, 1992). To de-
termine the number of infectious units per ml of a virus
stock, wells containing between 20 and 500 blue cells
were counted under the light microscope, and the mean
values calculated and multiplied by the virus dilution.
Values obtained for serially-diluted virus samples be-
haved linearly within this range. Uninfected wells con-
sistently exhibited fewer than five cells per well. The
infectivity of a given virus was calculated as the number
of infectious units per ml virus stock divided by the cpm
of reverse transcriptase activity contained in 10 ml su-
pernatant.
Infections of T cell lines were performed by inoculating
cells (5 3 105) in 1-ml volumes with amounts of virus
stocks normalized for reverse transcriptase activity. After
overnight incubation, the cells were pelleted to remove
the virus inocula and resuspended in 2 ml fresh medium
containing 2.5 mM cyclosporin A (Sigma). Supernatants
were sampled every 3 days for virus production, and the
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cultures were split 1:5 or 1:10 as necessary into fresh
medium with or without cyclosporin A.
Reverse transcriptase assays were performed in du-
plicate as previously described (Aiken and Trono, 1995).
Values obtained were all within the linear range of the
assay, and varied between 2000 and 80,000 cpm 3H, with
background values between 100 and 200 cpm. The val-
ues of reverse transcriptase activity measured using this
assay correlated well with p24 concentrations of the
virus stocks determined by ELISA.
Protein analyses
HIV-1 virions were pelleted by ultracentrifugation of
virus supernatants (8 ml) through a 2 ml layer of 20%
sucrose in PBS for 2 h at 100,000 g in a Beckman SW41
rotor. Pellets were resuspended in 1 ml PBS and recen-
trifuged at 100,000 g for 30 min in a Sorvall RPA45 rotor.
The resulting pellet was resuspended in lysis buffer (20
mM Tris-HCl pH 7.5, 100 mM NaCl, 0.5% NP40) and
assayed for p24 by ELISA (Biotech Research Laborato-
ries). Immunoblotting of viral proteins was performed by
subjecting samples of viral lysates containing 100 ng p24
to electrophoresis on 4 to 20% gradient acrylamide gels
containing SDS. Proteins were transferred to nitrocellu-
lose, and blocked overnight in TBST (10 mM Tris-HCl pH
8.0, 150 mM NaCl, 0.05% Tween 20) containing 5% nonfat
dry milk. Blots were probed with rabbit anti-Nef (Aiken
and Trono, 1995), rabbit anti-CyPA (the generous gift of
Louis Henderson), and mouse anti-CA (obtained from the
NIH AIDS Research and Reference Reagent Program).
Protein bands were revealed using chemiluminescent
detection (ECL, Amersham Corp.).
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